From Cipla to Glenmark, pharma companies' double-digit growth in doubt

Govt's proposed changes in pricing policy could play spoilsport

Domestic drugmakers are targeting double-digit growth in 2018-19 on the back of product launches and expansion in new therapies but the government’s proposed pricing changes could put the brakes on their plans.

Cipla has guided for $1 billion (around Rs 67 billion) in domestic sales in 2018-19 with product launches and an uptick in its cardio-metabolic drugs. Cipla had sales of around Rs 59 billion in the last fiscal year and will have to achieve around 15 per cent growth to reach sales of $1 billion.

Glenmark too is targeting 12-15 per cent with the launch of differentiated products and